Yifei Sanjie Pill reduces the 2-year progression rate of high-risk pulmonary nodules in adults with mixed ground-glass nodules ≤8 mm.
This multicenter RCT protocol evaluates YFSJ versus placebo for preventing progression of high-risk pulmonary nodules over 2 years. The primary outcome is progression rate defined by ≥2 mm increase in diameter, ≥1 mm increase in solid component, or new solid component. The study enrolled 589 participants and will analyze results using Kaplan-Meier and Cox regression.
This article is automatically generated from the structured evidence profile behind the claim above. Scores reflect the quality and quantity of available research, not clinical advice.
Yifei Sanjie Pill reduces the 2-year progression rate of high-risk pulmonary nodules in adults with mixed ground-glass nodules ≤8 mm. The current body of evidence comprises 1 study, including 1 randomized controlled trial. EvidenceHub rates the overall confidence at 42/100 (low).
The Claim
Yifei Sanjie Pill reduces the 2-year progression rate of high-risk pulmonary nodules in adults with mixed ground-glass nodules ≤8 mm.
This conclusion is most relevant to: Adults aged 18–80 years with single or multiple mixed ground-glass nodules measuring ≤8 mm.
What the Research Shows
The conclusion draws on 1 linked study. Highlights from the cited literature:
- ▸Clinical Study on the Prevention of High-Risk Pulmonary Nodule Progression With Yifei Sanjie Pill: Protocol for a Multicenter Randomized Controlled Trial. (JMIR research protocols, 2026) —
How It Works
The proposed biological pathway:
- ▸YFSJ is an 8-herb traditional Chinese medicine formula
- ▸Previously studied as adjunctive treatment for non-small cell lung cancer
- ▸May modulate plasma biomarkers and malignancy risk index
- ▸Result: potential reduction in nodule progression
Who Might Benefit
Evidence fit by population:
- ▸Adults aged 18–80 years with single or multiple mixed ground-glass nodules measuring ≤8 mm
Recommended Dose
2 packets twice daily
Limitations & Caveats
Important context when interpreting this evidence:
- ▸Results are not yet available; this is a protocol paper
- ▸The study is ongoing with final analysis expected in 2028
- ▸Placebo-controlled but blinding details not fully described
Frequently Asked Questions
What is Yifei Sanjie Pill?▼
YFSJ is an 8-herb traditional Chinese medicine formula previously studied as an adjunctive treatment for non-small cell lung cancer.
Who is eligible for this trial?▼
Adults aged 18–80 years with single or multiple mixed ground-glass nodules ≤8 mm.
What is the primary outcome of the study?▼
The 2-year pulmonary nodule progression rate, defined as an increase in lesion diameter ≥2 mm, increase in solid component ≥1 mm, or new solid component.
When will the results be available?▼
Database lock and primary analysis are planned for early 2028, with first results expected in spring or summer 2028.
References
- 1.An B, Lin J, Wang J, Chen Z, Guan M, Li Y, Qi X, Sun L, Lin L. “Clinical Study on the Prevention of High-Risk Pulmonary Nodule Progression With Yifei Sanjie Pill: Protocol for a Multicenter Randomized Controlled Trial..” JMIR research protocols, 2026. PMID: 42456132 DOI: 10.2196/78534